The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
Open accessAbstract
Cannabidiol (CBD) is ubiquitous in state-based medical cannabis programs and consumer products for complementary health or recreational use. CBD has intrinsic pharmacologic effects and associated adverse drug events (ADEs) along with the potential for pharmacokinetic and pharmacodynamic drug–drug interactions (DDIs). Given CBD use among patients with complex conditions and treatment regimens, as well as its expanded consumer use, awareness of potential safety issues with CBD is needed. Prescribing information for federally approved products containing CBD were reviewed. Data on ADEs and DDIs were extracted and summarized. Nearly one-half of CBD users experienced ADEs, which displayed a general dose-response relationship. Common ADEs include transaminase elevations, sedation, sleep disturbances, infection, and anemia. Given CBD effects on common biological targets implicated in drug metabolism (e.g., CYP3A4/2C19) and excretion (e.g., P-glycoprotein), the potential for DDIs with commonly used medication is high. General clinical recommendations of reducing substrate doses, monitoring for ADEs, and finding alternative therapy should be considered, especially in medically complex patients. CBD is implicated as both a victim and perpetrator of DDIs and has its own ADE profile. These effects should be considered in the risk-benefit assessment of CBD therapy and patients and consumers made aware of potential safety issues with CBD use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · cited 2×
“CYP450 enzymes are implicated in the primary metabolism and biotransformation of the majority of therapeutic agents and xenobiotics [37].”
BackgroundCannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Zou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,343
Chemical constituents of marijuana: The complex mixture of natural cannabinoids
ElSohly, M. A., & Slade, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.011 · Cited by 1,094
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
Labeling Accuracy of Cannabidiol Extracts Sold Online
Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017) · JAMA · doi:10.1001/jama.2017.11909 · Cited by 529
Phytochemistry of Cannabis sativa L.
ElSohly, M. A., Radwan, M. M., Gul, W., Chandra, S., & Galal, A. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_1 · Cited by 521
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Medical complications of anorexia nervosa and bulimia nervosa
Mitchell, J. E., & Crow, S. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000228768.79097.3e · Cited by 492
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
Pertwee, R. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444
Fässberg, M. M., Cheung, G., Canetto, S. S., Erlangsen, A., Lapierre, S., Lindner, R., Draper, B., Gallo, J. J., Wong, C., Wu, J., et al. (2016) · Aging & Mental Health · doi:10.1080/13607863.2015.1083945 · Cited by 423
Brown, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707481 · Cited by 409
Interactions between cannabidiol and commonly used antiepileptic drugs
Gaston, T. E., Bebin, E. M., Cutter, G. R., Liu, Y., Szaflarski, J. P., & Program, T. U. C. (2017) · Epilepsia · doi:10.1111/epi.13852 · Cited by 349
A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy
Sexton, M., Cuttler, C., Finnell, J. S., & Mischley, L. K. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0007 · Cited by 336
Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing
Van Driest, S., Shi, Y., Bowton, E., Schildcrout, J., Peterson, J., Pulley, J., Denny, J., & Roden, D. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.229 · Cited by 334
Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.018 · Cited by 322
Ujváry, I., & Hanuš, L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0012 · Cited by 298
Lucas, P., & Walsh, Z. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.01.011 · Cited by 271
Han, B. H., Sherman, S., Mauro, P. M., Martins, S. S., Rotenberg, J., & Palamar, J. J. (2017) · Addiction · doi:10.1111/add.13670 · Cited by 249
Vaporization as a Smokeless Cannabis Delivery System: A Pilot Study
Abrams, D. I., Vizoso, H. P., Shade, S. B., Jay, C., Kelly, M. E., & Benowitz, N. L. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100200 · Cited by 243
Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S., & Huestis, M. A. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.152439 · Cited by 231
Yamaori, S., Ebisawa, J., Okushima, Y., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.02.017 · Cited by 223
Vandrey, R., Herrmann, E. S., Mitchell, J. M., Bigelow, G. E., Flegel, R., LoDico, C., & Cone, E. J. (2017) · Journal of Analytical Toxicology · doi:10.1093/jat/bkx012 · Cited by 215
Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19
Jiang, R., Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-129 · Cited by 199
Cannabidiol in Humans—The Quest for Therapeutic Targets
Zhornitsky, S., & Potvin, S. (2012) · Pharmaceuticals · doi:10.3390/ph5050529 · Cited by 197
Schwope, D. M., Karschner, E. L., Gorelick, D. A., & Huestis, M. A. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.171777 · Cited by 183
Schier, A. R. D. M., Ribeiro, N. D. C. R., Coutinho, D. C. O., Machado, S. E. D. C., Arias-Carrión, Ó., Crippa, J. A. S., Zuardi, A. W., Nardi, A. E., & Silva, A. R. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140612114838 · Cited by 177
Medical Cannabinoids in Children and Adolescents: A Systematic Review
Wong, S. S., & Wilens, T. E. (2017) · PEDIATRICS · doi:10.1542/peds.2017-1818 · Cited by 172
Yamaori, S., Kushihara, M., Yamamoto, I., & Watanabe, K. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.028 · Cited by 165
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.041384 · Cited by 164
Yamaori, S., Koeda, K., Kushihara, M., Hada, Y., Yamamoto, I., & Watanabe, K. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rg-107 · Cited by 142
Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-236 · Cited by 136
Jadoon, K. A., Tan, G. D., & O’Sullivan, S. E. (2017) · JCI Insight · doi:10.1172/jci.insight.93760 · Cited by 136
Endocannabinoid System: A Multi-Facet Therapeutic Target
Kaur, R. J., Ambwani, S. R., & Singh, S. (2016) · Current Clinical Pharmacology · doi:10.2174/1574884711666160418105339 · Cited by 135
Ferro, M. A. (2015) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796015000700 · Cited by 97
Drug-Induced Megaloblastic Anemia
Hesdorffer, C. S., & Longo, D. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1508861 · Cited by 88
Saabi, A. A., Allorge, D., Sauvage, F., Tournel, G., Gaulier, J., Marquet, P., & Picard, N. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047878 · Cited by 82
Clinical Association Between Pharmacogenomics and Adverse Drug Reactions
Zhou, Z.-W., Chen, X.-W., Sneed, K., Yang, Y.-X., Zhang, X., He, Z.-X., Chow, K., Yang, T., Duan, W., & Zhou, S.-F. (2015) · Drugs · doi:10.1007/s40265-015-0375-0 · Cited by 78
Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., Guimarães, F. S., Tumas, V., & SANTOS, R. G. D. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00982-6 · Cited by 76
Targeting the CB2receptor for immune modulation
Lunn, C. A., Reich, E., & Bober, L. A. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.5.653 · Cited by 68
Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2
Arnold, W. R., Weigle, A. T., & Das, A. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.03.016 · Cited by 56
Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?
Martin, J. H., Schneider, J., Lucas, C. J., & Galettis, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0599-0 · Cited by 55
Rovare, V. P. D. [., Magalhães, G. P. A., Jardini, G. D. A., Beraldo, M. L., Gameiro, M. O., Agarwal, A., Luvizutto, G. J., Ramos, L. D. P., Camargo, S. E. A., de Oliveira, L. D., et al. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.08.010 · Cited by 45
Yamaori, S., Okushima, Y., Yamamoto, I., & Watanabe, K. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.03.007 · Cited by 25
Madras, B. K. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.269795 · Cited by 8
Cited by
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307
Page, R. L., Allen, L. A., Kloner, R. A., Carriker, C. R., Martel, C., Morris, A. A., Piano, M. R., Rana, J. S., Saucedo, J. F., & On behalf of the American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research (2020) · Circulation · doi:10.1161/cir.0000000000000883 · Cited by 260
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00326-8 · Cited by 143
de Faria, S. M., de Morais Fabrício, D., Tumas, V., Castro, P. C., Ponti, M. A., Hallak, J. E., Zuardi, A. W., Crippa, J. A. S., & Chagas, M. H. N. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119895536 · Cited by 140
“Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations
MacCallum, C. A., Lo, L. A., & Boivin, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.002 · Cited by 71
Metadata
- Authors
- Brown, J., & Winterstein, A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2019-07-08
- Volume
- 8
- Issue
- 7
- Pages
- 989
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2955589096
- Cited by
- 295
- References
- 53
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.